- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02945982
Treatment of Moderate and Severe Cirrhotic Portal Hypertension Due to HBV With Fuzheng Huayu and Entecavir
February 11, 2020 updated by: Liu Chenghai, ShuGuang Hospital
A Randomized, Placebo-Controlled, Open-label, Multi-Center Study to Assess the Efficacy and Safety of Fuzheng Huayu Combined With Entecavir and Carvedilol in Moderate and Severe Cirrhotic Portal Hypertension Due to Hepatitis B Virus
Portal hypertension is a common pathology in chronic liver disease, particularly in liver cirrhosis.
Hepatitis B Virus (HBV) is one of most etiologies of liver cirrhosis in China.
The basic reason for portal hypertension in HBV is the largely deposition of hepatic extracellular matrixes which causes high pressure in liver vessels.
One of the most common symptoms of cirrhotic portal hypertension is gastroesophageal varices.The effective inhibition of HBV can partially stop or reverse liver fibrosis in patients with chronic Hepatitis and liver cirrhosis due to HBV and the anti-fibrotic strategy focusing on the regulation of hepatic extracellular matrix may have a great benefit.
Therefore, antivirals therapy is also a basic treatment for low-grade cirrhotic portal hypertension.
Fuzheng Huayu has been found to enhance the degradation of collagens in fibrotic liver and have a good action against liver fibrosis in patients with chronic hepatitis B. However, there are no high quality clinical evidences which can demonstrate if the combination of anti-viral and anti-fibrotic therapy can relieve the pressure of liver vessels and decline incidence rate and bleeding rate of gastroesophageal varices.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
The primary objective of this study is to establish the safety and efficacy of the combination of Entecavir and Fuzheng Huayu for reverse rate of gastroesophageal varices in patients with Moderate and Severe cirrhotic portal hypertension due to hepatitis B virus.
Study Type
Interventional
Enrollment (Anticipated)
184
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: JING LV, MD
- Phone Number: +86-21-20256521
- Email: liver125@126.com
Study Locations
-
-
-
Shanghai, China
- Recruiting
- Shanghai Zhongshan Hospital
-
Contact:
- Wei Jiang
-
Shanghai, China
- Recruiting
- Ruijin Hospital
-
Contact:
- hui Wang
-
Shanghai, China
- Recruiting
- Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- More than 6 months history of serum positive HBsAg
- Abdominal ultrasonogram or CT scan or liver-biopsy specimen indicates liver cirrhosis
- Age 18-65
- Child-Pugh<7 (Stage A)
- Without portal hypertension(Endoscopy indicates no signs of gastroesophageal varices.)
- Moderate and Severe of portal hypertension(Endoscopy indicates signs of gastroesophageal varices that is line shape without red wales or spots and less than 0.3cm of diameter.)
- The patient or the patient's guardian agrees to participate the random controlled trial and sign the Informed Consent Form.
Exclusion Criteria:
- Primary Lamivudine, Adefovir dipivoxil and Entecavir resistance
- Decompensated cirrhosis、The Child-Pugh score≥7
- Low-grade Cirrhotic Portal Hypertension.
- Severe grade of portal hypertension(Endoscopy indicates signs of gastroesophageal varices that is catenulate/nodular shape with or without red wales or spots and more than 1.0cm of diameter.)
- Decompensated liver cirrhosis Liver cancer
- Liver histology conforming to other chronic liver diseases, such as moderate or severe non-alcoholic fatty liver disease(more than 1/3 steatosis in liver ), chronic hepatitis C, chronic hepatitis D, autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, inherited metabolic liver disease, drug or toxic induced liver injury, parasitic infections, alcoholic liver disease.
- Have psychiatric history or uncontrollable epilepsy patient.
- Uncontrollable diabetic patient
- History of hemoglobin disease (such as alpha- or beta-thalassemia, sickle cell disease, spherocytosis) or patients with toxic or autoimmune hemolytic anemia.
- Severe background disease like chronic respiratory failure, circulatory failure, kidney failure etc.
- In situ organ transplantation (such as liver, kidney, lung and heart) or bone marrow transplantation and stem cell transplantation.
- Immunocompromised patients: such as HIV infection or take immunosuppressor or glucocorticoid (such as cyclosporin, azathioprine, adrenocortical hormone) within 3 months or chemotherapy drugs (such as cyclophosphamide, ammonia and cancer chemotherapy) and radioactive therapy.
- Gestation or lactation period women and women who plan to get pregnant during the study period.
- Patient who are allergy to the experimental drug.
- Using history of anti-viral or anti-fibrosis drug within 6 months.
- Patients who are participating other trials.
- Other situation where PI thinks the patient should be excluded.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Entecavir/Carvedilol
Tablet with Entrcavir and Carvedilol
|
The subjects will be taking half a Carvedilol per day at first week and one Carvedilol per day from second week.
At the same time,the subjects will be taking one Entecavir tablet per day for 96 weeks.
|
Experimental: Entecavir/Carvedilol/ Fuzheng Huayu
Tablet with Entrcavir and Carvedilol+ Tablet with Fuzheng Huayu
|
The subjects will be taking half a Carvedilol tablet per day at first week and one Carvedilol tablets per day from second week.
At the same time,the subjects will be taking one Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 96 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of clinical events: Variceal hemorrhage, Ascites, Encephalopathy, etc
Time Frame: 96 weeks
|
96 weeks
|
Grading varices
Time Frame: 96 weeks
|
96 weeks
|
Incidence of liver cancer
Time Frame: 96 weeks
|
96 weeks
|
Noninvasive portal hypertension index
Time Frame: 96 weeks
|
96 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: CHENGHAI LIU, PHD,MD, ShuGuang Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 5, 2018
Primary Completion (Anticipated)
June 1, 2020
Study Completion (Anticipated)
June 1, 2021
Study Registration Dates
First Submitted
October 23, 2016
First Submitted That Met QC Criteria
October 24, 2016
First Posted (Estimate)
October 26, 2016
Study Record Updates
Last Update Posted (Actual)
February 13, 2020
Last Update Submitted That Met QC Criteria
February 11, 2020
Last Verified
February 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Liver Diseases
- Hypertension
- Hypertension, Portal
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Anti-Infective Agents
- Antiviral Agents
- Protective Agents
- Membrane Transport Modulators
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Antioxidants
- Adrenergic alpha-1 Receptor Antagonists
- Adrenergic alpha-Antagonists
- Entecavir
- Carvedilol
Other Study ID Numbers
- SGHLC20161023004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Portal Hypertension
-
Assistance Publique - Hôpitaux de ParisActive, not recruitingIntrahepatic Non Cirrhotic Portal HypertensionFrance
-
Centro Hospitalar De São João, E.P.E.CompletedClinically Significant Portal HypertensionPortugal
-
University Hospital, ToursCompletedCirrhotic Portal HypertensionFrance
-
Icahn School of Medicine at Mount SinaiNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedPortal Hypertension | Clinically Significant Portal HypertensionUnited States
-
University Hospital, GhentCompletedEvaluation of Efficacy and Safety of Somatostatin Used as Inflow Modulator in Liver Transplantation.Liver Transplant With Clinically Significant Portal HypertensionBelgium
-
Ain Shams UniversityCompleted
-
Universidade Federal do Rio de JaneiroNot yet recruitingPortal Hypertension | Idiopathic Non-Cirrhotic Portal Hypertension | Non-Cirrhotic Portal Hypertension | Vascular Disorder of Liver | Non-Cirrhotic Portal Fibrosis | Regenerative Nodular Hyperplasia | Incomplete Septal Cirrhosis | Obliterative Portal Venopathy | Hepatoportal Sclerosis | Idiopathic Portal...Brazil
-
Assiut UniversityUnknownPredicting Liver Cell Failure & Portal Hypertension in LCEgypt
-
University Hospital, BonnCompleted
-
Tanta UniversityCompleted
Clinical Trials on Entecavir+Carvedilol
-
Sunshine Lake Pharma Co., Ltd.Suspended
-
ShuGuang HospitalBeijing YouAn Hospital; Beijing Ditan Hospital; Shanghai Zhongshan Hospital; Tongji... and other collaboratorsUnknownLiver Cirrhosis Due to Hepatitis B VirusChina
-
Beijing Friendship HospitalPeking University; Peking University First Hospital; Peking University People... and other collaboratorsCompleted
-
Taipei Veterans General Hospital, TaiwanBristol-Myers SquibbCompletedProphylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B (HBVNHL)Hepatitis B | Non Hodgkin's LymphomaTaiwan
-
ShuGuang HospitalShanghai Zhongshan Hospital; Ruijin Hospital; Shanghai Public Health Clinical... and other collaboratorsUnknown
-
Beijing Friendship HospitalPeking University; Peking University First Hospital; Peking University People... and other collaboratorsCompleted
-
Peking UniversityUnknown
-
National Taiwan University HospitalUnknownHBV/HCV Co-infectionTaiwan
-
Beijing Continent Pharmaceutical Co, Ltd.Completed
-
Taipei Veterans General Hospital, TaiwanChina Medical University Hospital; Chang Gung Memorial Hospital; Changhua Christian...UnknownChronic Hepatitis B